INV102 / Invirsa - LARVOL DELTA

INV-102 Significantly Improves Visual Acuity Compared to Vehicle Control in Dry Eye Subjects with Diabetes: A Sub Analysis of a Phase 2 Randomized Controlled Clinical Trial (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • P2 data • Dry Eye Disease • Ophthalmology • PAX6

INV-102 Significantly Improves Clinical Score Versus Vehicle in the Fellow Eye of Subjects with Acute Infectious Keratoconjunctivitis (AIK): A Randomized Controlled Clinical Trial (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • TP53

Study of INV-102 Ophthalmic Solution in Adults With Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Invirsa, Inc. | Trial completion date: Mar 2025 ➔ Aug 2025 | Trial primary completion date: Mar 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Study of INV-102 Ophthalmic Solution in Adults With Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Invirsa, Inc.

New P2 trial • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis (clinicaltrials.gov) - P2 | N=93 | Completed | Sponsor: Invirsa, Inc. | Recruiting ➔ Completed

Trial completion • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease (clinicaltrials.gov) - P2 | N=109 | Completed | Sponsor: Invirsa, Inc. | Recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: Invirsa, Inc.

New P2 trial • Dry Eye Disease • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis (clinicaltrials.gov) - P2 | N=102 | Recruiting | Sponsor: Invirsa, Inc. | Suspended ➔ Recruiting | Trial completion date: Dec 2023 ➔ Aug 2024 | Trial primary completion date: Oct 2023 ➔ Jun 2024

Enrollment open • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Treatment of Sulfur Mustard Corneal Injury by Augmenting the DNA Damage Response (DDR): A Novel Approach. (PubMed, J Pharmacol Exp Ther) - "Here we demonstrate that a dilithium salt of adenosine diphosphoribose (INV-102) increases protein levels of p53 and Sirtuin 6, upregulates transcription of BRCA1/2, enhances gH2AX focus formation and promotes assembly of repair complexes at DSBs...Significance Statement Sulfur Mustard Gas corneal injury currently has no therapeutic treatment. This study aims to show the therapeutic potential of activating the body's natural DDR to activate tissue repair."

Journal • Corneal Abrasion • Ophthalmology • BRCA1 • BRCA2

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis (clinicaltrials.gov) - P2 | N=102 | Suspended | Sponsor: Invirsa, Inc. | Recruiting ➔ Suspended

Trial suspension • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=84 | Completed | Sponsor: Invirsa, Inc. | Active, not recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Invirsa Completes $7.7M Series B Financing (Businesswire) - "Invirsa...announced the closing of a $7.7 million Series B financing completed in April earlier this year....The financing advances Invirsa's lead product candidate, INV-102, for treatment of conditions associated with DNA damage. Funds will support a series of Phase 2 studies in conditions including...dry eye disease...In addition, funds will support Phase 3 preparation. In addition, funds will support Phase 3 preparation."

Financing • Dry Eye Disease • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis (clinicaltrials.gov) - P2 | N=102 | Recruiting | Sponsor: Invirsa, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=84 | Active, not recruiting | Sponsor: Invirsa, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Dry Eye Disease • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis (clinicaltrials.gov) - P2 | N=102 | Not yet recruiting | Sponsor: Invirsa, Inc.

New P2 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Invirsa, Inc.

New P1/2 trial • Dry Eye Disease • Ophthalmology